BiotechTube
GlyProVac

GlyProVac

Copenhagen, Denmark· Est.
glyprovac.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.3M

Overview

GlyProVac is a Danish private biotech leveraging its proprietary BEMAP platform to discover and develop bacterial vaccines targeting O-linked glycoproteins, a largely untapped reservoir of antigenic targets. Its lead program, GPV02, is a preclinical vaccine candidate with pan-E. coli potential for UTIs, neonatal sepsis, and diarrheal diseases. The company is funded by a mix of private placements, non-dilutive grants including from CARB-X and Horizon Europe, and is advancing its technology through strategic collaborations with academic and industry partners.

Infectious DiseaseAntimicrobial Resistance

Technology Platform

BEMAP (Beta-Elimination followed by Michael Addition with a Phosphonic acid tag) – a mass spectrometry-based platform for discovering O-linked glycosylated bacterial proteins to use as novel vaccine antigens.

Funding History

2
Total raised:$4.3M
Grant$1.8M
Seed$2.5M

Opportunities

The global AMR crisis creates a urgent, large-scale demand for novel preventative solutions like vaccines.
GlyProVac's platform targets high-prevalence, high-burden infections (UTIs, neonatal sepsis) with no effective vaccines, representing greenfield markets.
The technology's applicability to multiple WHO priority pathogens (E.
coli, Pseudomonas, Shigella) offers a broad pipeline potential from a single platform.

Risk Factors

The company is at a high-risk preclinical stage with an unproven vaccine concept centered on bacterial O-glycosylation.
Manufacturing consistently glycosylated protein antigens at scale presents a significant technical hurdle.
Future success depends on overcoming scientific risks, out-competing other vaccine modalities, and securing major partnership or funding for costly clinical trials.

Competitive Landscape

GlyProVac competes in the bacterial vaccine space against large pharma, other biotechs developing novel platforms (mRNA, conjugate vaccines), and companies with specific UTI candidates (e.g., Janssen's VAC524 trial). Its key differentiation is the focus on native O-linked glycoproteins as antigens, a niche largely unexplored by competitors who typically use non-glycosylated or differently glycosylated (e.g., polysaccharide-conjugate) antigens.

More companies in Immunotherapy / Immuno-Oncology →More companies in Denmark →